FDA early alert on four lots of Edwards Commander M delivery systems for SAPIEN M3; EACTS pooled low-risk trials show late TAVI vs SAVR mortality signal; REF-TAVR conduction system pacing after TAVR.

DEDICATE-DZHK6 registry transportability analysis tempers the TAVI vs SAVR benefit (EACTS 2026); CMS AR-TAVR comment period closed 10 Oct with societies backing coverage under CED.